Drug Prices Set Under IRA Could Be Less Than Actual Value, Researchers Say

As negotiators hash out prices for certain top-selling Medicare Part D drugs, the maximum fair price (MFP) could ultimately be far below the actual value that the drug offers to patients, according to researchers at the Tufts Center for the Study of Drug Development (CSDD).
Source: Drug Industry Daily